Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$10.83 - $18.41 $32,511 - $55,266
-3,002 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$13.07 - $18.84 $13,932 - $20,083
1,066 Added 55.06%
3,002 $54,000
Q2 2021

Aug 17, 2021

BUY
$16.52 - $20.4 $31,982 - $39,494
1,936 New
1,936 $33,000
Q4 2019

Feb 14, 2020

SELL
$15.87 - $23.12 $27,772 - $40,460
-1,750 Closed
0 $0
Q2 2019

Aug 14, 2019

SELL
$31.0 - $36.3 $43,307 - $50,711
-1,397 Reduced 44.39%
1,750 $62,000
Q4 2018

Feb 13, 2019

BUY
$30.43 - $56.65 $15,975 - $29,741
525 Added 20.02%
3,147 $102,000
Q3 2018

Nov 13, 2018

BUY
$46.46 - $68.49 $121,818 - $179,580
2,622 New
2,622 $160,000
Q2 2018

Aug 13, 2018

SELL
$46.25 - $104.45 $7,492 - $16,920
-162 Closed
0 $0
Q1 2018

May 14, 2018

BUY
$57.4 - $108.44 $9,298 - $17,567
162 New
162 $17,000

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $171M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Itau Unibanco Holding S.A. Portfolio

Follow Itau Unibanco Holding S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Itau Unibanco Holding S.A., based on Form 13F filings with the SEC.

News

Stay updated on Itau Unibanco Holding S.A. with notifications on news.